Higher sTNF-RII Associated with Reduced Memory Functioning Among BC Patients Before Treatment
Menée aux Etats-Unis à partir de données portant sur 174 patientes atteintes d'un cancer du sein récemment diagnostiqué et sur 174 témoins, cette étude évalue l'association entre des comorbidités, le niveau de trois cytokines pro-inflammatoires circulantes et des dysfonctionnements neurocognitifs avant les traitements anti-cancéreux
Pretreatment cytokine levels, specifically soluble TNF receptor type two (sTNF-RII), are associated with reduced memory performance among newly-diagnosed, post-menopausal breast cancer (BC) patients prior to receipt of surgery and/or adjuvant therapy, according to a new study published June 22 in the JNCI: Journal of the National Cancer Institute.
Neurocognitive dysfunction was associated with pro-inflammatory cytokines among BC survivors in a previous report, and was attributed to chemotherapy effects. However, it … [...]
Journal of the National Cancer Institute , communiqué de presse, 2015